Jiangxi Institute of Biological Products (HKSE:06915) EV-to-FCF: (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06915 Jiangxi Institute of Biological Products Inc HKSE:06915
23 GF Score
Price HK$16.72
! 3 Warning Signs
View Full Analysis

What is Jiangxi Institute of Biological Products EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Jiangxi Institute of Biological Products's Enterprise Value is HK$4,952.1 Mil. Jiangxi Institute of Biological Products does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Jiangxi Institute of Biological Products's EV-to-FCF at this moment.

The historical rank and industry rank for Jiangxi Institute of Biological Products's EV-to-FCF or its related term are showing as below:

HKSE:06915' s EV-to-FCF Range Over the Past 10 Years
Min: 56.78   Med: 184.49   Max: 271.77
Current: 215.64

During the past 3 years, the highest EV-to-FCF of Jiangxi Institute of Biological Products was 271.77. The lowest was 56.78. And the median was 184.49.

HKSE:06915's EV-to-FCF is ranked worse than
93.49% of 568 companies
in the Drug Manufacturers industry
Industry Median: 20.11 vs HKSE:06915: 215.64

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-09-10), Jiangxi Institute of Biological Products's stock price is HK$16.72. Jiangxi Institute of Biological Products does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Jiangxi Institute of Biological Products's PE Ratio (TTM) at this moment.

Jiangxi Institute of Biological Products  (HKSE:06915) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Jiangxi Institute of Biological Products's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=16.72/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Jiangxi Institute of Biological Products EV-to-FCF Related Terms

Jiangxi Institute of Biological Products EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Jiangxi Institute of Biological Products's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangxi Institute of Biological Products EV-to-FCF Chart

Jiangxi Institute of Biological Products Annual Data
Trend Dec23 Dec24 Dec25
EV-to-FCF
0.00 0.00 0.00

Jiangxi Institute of Biological Products Semi-Annual Data
Dec23 Dec24 Dec25
EV-to-FCF 0.00 0.00 0.00

HKSE:06915 vs LLY, JNJ, ABBV: EV-to-FCF Comparison

For the Drug Manufacturers - General subindustry, Jiangxi Institute of Biological Products's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jiangxi Institute of Biological Products EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangxi Institute of Biological Products's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Jiangxi Institute of Biological Products's EV-to-FCF falls into.


HKSE:06915
23GF Score
Jiangxi Institute of Biological Products Inc HKSE:06915
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangxi Institute of Biological Products EV-to-FCF Calculation

Jiangxi Institute of Biological Products's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4952.135/
=

Jiangxi Institute of Biological Products Business Description

Address No. 198 Huoju Avenue, Jinggangshan Economic and Technological Development Zone, Jiangxi Province, Ji’an, CHN
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
23GF Score

Get the complete analysis for HKSE:06915

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$16.72
Price